RISANKIZUMAB (Skyrizi®)

Clinical Indication

For previously treated moderately to severely active Crohn's disease

Comments

In line with NICE TA888

Date of classification

October 2023

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.